Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19915011
Quoyer J, et al. (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285, 1989-2002 19915011
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S112-p - BAD (mouse)
Modsite: ETRsRHssyPAGtEE SwissProt Entrez-Gene
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
U0126 GLP-1 inhibit treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits response
GLP-1 ARRB1 (mouse) increase

S155-p - BAD (mouse)
Modsite: GRELRRMsDEFEGsF SwissProt Entrez-Gene
Orthologous residues
BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 no change compared to control

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
H-89 GLP-1 inhibit treatment-induced increase inhibition at 5 min but not 20 min
U0126 GLP-1 inhibit treatment-induced increase
nifedipine GLP-1 no effect upon treatment-induced increase
wortmannin GLP-1 no effect upon treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits, ARRB1 knockout abrogates response

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
H-89 GLP-1 inhibit treatment-induced increase inhibition at 5 min but not 20 min
U0126 GLP-1 inhibit treatment-induced increase
nifedipine GLP-1 no effect upon treatment-induced increase
wortmannin GLP-1 no effect upon treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits, ARRB1 knockout abrogates response

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
H-89 GLP-1 inhibit treatment-induced increase inhibition at 5 min but not 20 min
U0126 GLP-1 inhibit treatment-induced increase
nifedipine GLP-1 no effect upon treatment-induced increase
wortmannin GLP-1 no effect upon treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits, ARRB1 knockout abrogates response

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
H-89 GLP-1 inhibit treatment-induced increase inhibition at 5 min but not 20 min
U0126 GLP-1 inhibit treatment-induced increase
nifedipine GLP-1 no effect upon treatment-induced increase
wortmannin GLP-1 no effect upon treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits, ARRB1 knockout abrogates response

T562-p - p90RSK (mouse)
Modsite: AENGLLMtPCYtANF SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): T573‑p, p90RSK iso2 (human): T582‑p, p90RSK (mouse): T562‑p, p90RSK iso3 (mouse): , p90RSK (rat): T573‑p, p90RSK (chicken): T590‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  beta-pancreas, MIN6 (pancreatic)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GLP-1 increase
U0126 GLP-1 inhibit treatment-induced increase
GLP-1 ARRB1 (mouse) increase ARRB1 siRNA inhibits response